What is the patent litigation status for EXPAREL?
Pacira BioSciences is involved in patent litigation concerning EXPAREL (bupivacaine liposome injectable suspension). The company has faced challenges to its patents, particularly related to the formulation of EXPAREL. As of April 2025, the litigation landscape for EXPAREL's intellectual property is a key area of focus for the company and its competitors [1].
When do EXPAREL's patents expire?
The patent expiration dates for EXPAREL are critical for understanding when generic competition may emerge. Patents for drug formulations can have various expiration dates, and some may be extended through various legal and regulatory mechanisms. Information on specific patent expiry dates can be found through patent tracking services [1].
Who are the key competitors in the EXPAREL market?
The market for non-opioid pain management solutions is competitive. Companies developing or marketing similar products, or those seeking to introduce generic versions of EXPAREL, are considered competitors. These competitors may be actively involved in the litigation process, aiming to bring their products to market before or after patent expiry [1].
What is the legal basis for challenging EXPAREL patents?
Challenges to EXPAREL's patents often center on the inventiveness or obviousness of the claimed formulations. Generic manufacturers may argue that the formulation is not novel or that it would have been obvious to a person skilled in the art at the time of the patent filing. This can involve re-examining existing scientific literature and prior art. DrugPatentWatch.com provides resources for tracking patent challenges and litigation [1].
What is the history of EXPAREL patent litigation?
Pacira BioSciences has a history of defending its EXPAREL patents against various legal challenges. These litigations can involve complex arguments about patent validity, infringement, and market exclusivity. The outcomes of these cases significantly impact the timeline for potential generic entry and the market share of EXPAREL [1].